Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Diseases, Myeloid Malignancies
Methods: Data for this analysis were drawn from both trials listed above. Eligibility criteria for this analysis included patients with MDS or AML with TP53 mutation/deletion or EVI1 rearrangement who were transplanted with a single UM171 CB. Examined clinical outcomes included NRM, relapse, progression-free survival (PFS) and overall survival (OS) at 2- and 3-years post-transplant. PFS and OS were estimated by Kaplan-Meir method; relapse and NRM were calculated using cumulative incidence estimates.
Results: A total of 10 patients met inclusion criteria, 1 from the initial phase I-II trial and 9 from the phase II trial. Three patients had EVI1 rearrangements and 7 patients had TP53 mutation/deletion. One patient had MDS and 9 had AML. Patient characteristics included 9 men and 1 woman with a median age and weight of 50 years and 83kg, respectively. Median HCT-CI was 1(0-4). One patient (10%) had previously failed an allogeneic transplant. Conditioning regimen was myeloablative or reduced intensity. Median follow-up is 35 months. Three patients died from NRM (NRM was 11% for the entire group of 52 patients from both clinical trials). Cumulative incidence of relapse was 10% at 2 years and 22% at 3 years. OS and PFS at 2 years were both 60% (95%CI 36-99%) and at 3 years 48% (95%CI 25-94%).
Conclusion: We previously showed that UM171 expanded CBT permits the use of CB with a low NRM of 11% and that these grafts are highly effective in high/very high-risk malignancies. Subset analyses presented herein suggest that this technology has the potential to overcome the negative prognosis associated with TP53/EVI1 MDS/AML with OS and relapse at 24 months of 60% and 10%, respectively. These results compare quite favorably to previous publications with OS usually being reported at ≈20% at 2 years. The main limitation of our study is the low number of patients, and thus more patients are needed to confirm these results.
Disclosures: Cohen: ExCellThera: Consultancy, Patents & Royalties, Research Funding. Roy: Amgen: Consultancy; Sanofi: Consultancy; Janssen: Consultancy; Forus Therapeutics: Consultancy; ExCellThera Inc.: Patents & Royalties: Royalties from sales of UM17; AbbVie: Honoraria; Kite: Honoraria; Gilead: Honoraria; Astra Zeneca: Honoraria. Lachance: ExCellThera: Patents & Royalties. Delisle: Vextex: Honoraria. Roy: Kiadis Pharma: Consultancy, Other: Clinical trial support; CellProthera: Consultancy; Vor: Other: Advisory committee; C3i Center: Other: Chief Scientific Officier. Sauvageau: ExCellThera: Current Employment, Current equity holder in private company, Patents & Royalties, Research Funding.
See more of: Oral and Poster Abstracts